Literature DB >> 26429724

GNL3 and SKA3 are novel prostate cancer metastasis susceptibility genes.

Minnkyong Lee1, Kendra A Williams1, Ying Hu2, Jonathan Andreas1, Shashank J Patel1, Suiyuan Zhang3, Nigel P S Crawford4,5.   

Abstract

Prostate cancer (PC) is very common in developed countries. However, the molecular determinants of PC metastasis are unclear. Previously, we reported that germline variation influences metastasis in the C57BL/6-Tg(TRAMP)8247Ng/J (TRAMP) mouse model of PC. These mice develop prostate tumors similar to a subset of poor outcome, treatment-associated human PC tumors. Here, we used TRAMP mice to nominate candidate genes and validate their role in aggressive human PC in PC datasets and cell lines. Candidate metastasis susceptibility genes were identified through quantitative trait locus (QTL) mapping in 201 (TRAMP × PWK/PhJ) F2 males. Two metastasis-associated QTLs were identified; one on chromosome 12 (LOD = 5.86), and one on chromosome 14 (LOD = 4.41). Correlation analysis using microarray data from (TRAMP × PWK/PhJ) F2 prostate tumors identified 35 metastasis-associated transcripts within the two loci. The role of these genes in susceptibility to aggressive human PC was determined through in silico analysis using multiple datasets. First, analysis of candidate gene expression in two human PC datasets demonstrated that five candidate genes were associated with an increased risk of aggressive disease and lower disease-free survival. Second, four of these genes (GNL3, MAT1A, SKA3, and ZMYM5) harbored SNPs associated with aggressive tumorigenesis in the PLCO/CGEMS GWAS of 1172 PC patients. Finally, over-expression of GNL3 and SKA3 in the PC-3 human PC cell line decreased in vitro cell migration and invasion. This novel approach demonstrates how mouse models can be used to identify metastasis susceptibility genes, and gives new insight into the molecular mechanisms of fatal PC.

Entities:  

Keywords:  Genetic susceptibility; Metastasis; Mouse models; Prostate cancer; TRAMP

Mesh:

Substances:

Year:  2015        PMID: 26429724     DOI: 10.1007/s10585-015-9745-y

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  44 in total

1.  Multiple testing. Part I. Single-step procedures for control of general type I error rates.

Authors:  Sandrine Dudoit; Mark J van der Laan; Katherine S Pollard
Journal:  Stat Appl Genet Mol Biol       Date:  2004-06-09

2.  Synergy of p53 and Rb deficiency in a conditional mouse model for metastatic prostate cancer.

Authors:  Zongxiang Zhou; Andrea Flesken-Nikitin; David C Corney; Wei Wang; David W Goodrich; Pradip Roy-Burman; Alexander Yu Nikitin
Journal:  Cancer Res       Date:  2006-08-15       Impact factor: 12.701

3.  The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status.

Authors:  J K Gohagan; P C Prorok; R B Hayes; B S Kramer
Journal:  Control Clin Trials       Date:  2000-12

4.  The TRAMP mouse as a model for prostate cancer.

Authors:  A A Hurwitz; B A Foster; J P Allison; N M Greenberg; E D Kwon
Journal:  Curr Protoc Immunol       Date:  2001-11

Review 5.  Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches.

Authors:  T Karantanos; P G Corn; T C Thompson
Journal:  Oncogene       Date:  2013-06-10       Impact factor: 9.867

Review 6.  The genetic epidemiology of prostate cancer and its clinical implications.

Authors:  Rosalind Eeles; Chee Goh; Elena Castro; Elizabeth Bancroft; Michelle Guy; Ali Amin Al Olama; Douglas Easton; Zsofia Kote-Jarai
Journal:  Nat Rev Urol       Date:  2013-12-03       Impact factor: 14.432

7.  A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease.

Authors:  Ali Amin Al Olama; Zsofia Kote-Jarai; Fredrick R Schumacher; Fredrik Wiklund; Sonja I Berndt; Sara Benlloch; Graham G Giles; Gianluca Severi; David E Neal; Freddie C Hamdy; Jenny L Donovan; David J Hunter; Brian E Henderson; Michael J Thun; Michael Gaziano; Edward L Giovannucci; Afshan Siddiq; Ruth C Travis; David G Cox; Federico Canzian; Elio Riboli; Timothy J Key; Gerald Andriole; Demetrius Albanes; Richard B Hayes; Johanna Schleutker; Anssi Auvinen; Teuvo L J Tammela; Maren Weischer; Janet L Stanford; Elaine A Ostrander; Cezary Cybulski; Jan Lubinski; Stephen N Thibodeau; Daniel J Schaid; Karina D Sorensen; Jyotsna Batra; Judith A Clements; Suzanne Chambers; Joanne Aitken; Robert A Gardiner; Christiane Maier; Walther Vogel; Thilo Dörk; Hermann Brenner; Tomonori Habuchi; Sue Ingles; Esther M John; Joanne L Dickinson; Lisa Cannon-Albright; Manuel R Teixeira; Radka Kaneva; Hong-Wei Zhang; Yong-Jie Lu; Jong Y Park; Kathleen A Cooney; Kenneth R Muir; Daniel A Leongamornlert; Edward Saunders; Malgorzata Tymrakiewicz; Nadiya Mahmud; Michelle Guy; Koveela Govindasami; Lynne T O'Brien; Rosemary A Wilkinson; Amanda L Hall; Emma J Sawyer; Tokhir Dadaev; Jonathan Morrison; David P Dearnaley; Alan Horwich; Robert A Huddart; Vincent S Khoo; Christopher C Parker; Nicholas Van As; Christopher J Woodhouse; Alan Thompson; Tim Dudderidge; Chris Ogden; Colin S Cooper; Artitaya Lophatonanon; Melissa C Southey; John L Hopper; Dallas English; Jarmo Virtamo; Loic Le Marchand; Daniele Campa; Rudolf Kaaks; Sara Lindstrom; W Ryan Diver; Susan Gapstur; Meredith Yeager; Angela Cox; Mariana C Stern; Roman Corral; Markus Aly; William Isaacs; Jan Adolfsson; Jianfeng Xu; S Lilly Zheng; Tiina Wahlfors; Kimmo Taari; Paula Kujala; Peter Klarskov; Børge G Nordestgaard; M Andreas Røder; Ruth Frikke-Schmidt; Stig E Bojesen; Liesel M FitzGerald; Suzanne Kolb; Erika M Kwon; Danielle M Karyadi; Torben Falck Orntoft; Michael Borre; Antje Rinckleb; Manuel Luedeke; Kathleen Herkommer; Andreas Meyer; Jürgen Serth; James R Marthick; Briony Patterson; Dominika Wokolorczyk; Amanda Spurdle; Felicity Lose; Shannon K McDonnell; Amit D Joshi; Ahva Shahabi; Pedro Pinto; Joana Santos; Ana Ray; Thomas A Sellers; Hui-Yi Lin; Robert A Stephenson; Craig Teerlink; Heiko Muller; Dietrich Rothenbacher; Norihiko Tsuchiya; Shintaro Narita; Guang-Wen Cao; Chavdar Slavov; Vanio Mitev; Stephen Chanock; Henrik Gronberg; Christopher A Haiman; Peter Kraft; Douglas F Easton; Rosalind A Eeles
Journal:  Hum Mol Genet       Date:  2012-10-12       Impact factor: 6.150

8.  Cadm1 is a metastasis susceptibility gene that suppresses metastasis by modifying tumor interaction with the cell-mediated immunity.

Authors:  Farhoud Faraji; Yanli Pang; Renard C Walker; Rosan Nieves Borges; Li Yang; Kent W Hunter
Journal:  PLoS Genet       Date:  2012-09-20       Impact factor: 5.917

Review 9.  The many faces of neuroendocrine differentiation in prostate cancer progression.

Authors:  Stéphane Terry; Himisha Beltran
Journal:  Front Oncol       Date:  2014-03-25       Impact factor: 6.244

10.  RRP1B is a metastasis modifier that regulates the expression of alternative mRNA isoforms through interactions with SRSF1.

Authors:  M Lee; A M Dworkin; D Gildea; N S Trivedi; G B Moorhead; N P S Crawford
Journal:  Oncogene       Date:  2013-04-22       Impact factor: 9.867

View more
  29 in total

Review 1.  Genetic insights into the morass of metastatic heterogeneity.

Authors:  Kent W Hunter; Ruhul Amin; Sarah Deasy; Ngoc-Han Ha; Lalage Wakefield
Journal:  Nat Rev Cancer       Date:  2018-02-09       Impact factor: 60.716

2.  Mapping Complex Traits in a Diversity Outbred F1 Mouse Population Identifies Germline Modifiers of Metastasis in Human Prostate Cancer.

Authors:  Jean M Winter; Derek E Gildea; Jonathan P Andreas; Daniel M Gatti; Kendra A Williams; Minnkyong Lee; Ying Hu; Suiyuan Zhang; James C Mullikin; Tyra G Wolfsberg; Shannon K McDonnell; Zachary C Fogarty; Melissa C Larson; Amy J French; Daniel J Schaid; Stephen N Thibodeau; Gary A Churchill; Nigel P S Crawford
Journal:  Cell Syst       Date:  2016-12-01       Impact factor: 10.304

3.  MiR-133b suppresses the proliferation, migration and invasion of lung adenocarcinoma cells by targeting SKA3.

Authors:  Ming Zhang; Xiang Lan; Yong Chen
Journal:  Cancer Biol Ther       Date:  2021-10-28       Impact factor: 4.742

4.  Association of Nucleostemin Polymorphisms with Chronic Hepatitis B Virus Infection in Chinese Han Population.

Authors:  Jixia Li; Jinya Xu; Yangui Wang; Qin Li; Xilian Sun; Wen Fu; Bo Zhang
Journal:  Genet Test Mol Biomarkers       Date:  2022-05-16

5.  Mitochondrial Haplotype Alters Mammary Cancer Tumorigenicity and Metastasis in an Oncogenic Driver-Dependent Manner.

Authors:  Amanda E Brinker; Carolyn J Vivian; Devin C Koestler; Trevor T Tsue; Roy A Jensen; Danny R Welch
Journal:  Cancer Res       Date:  2017-10-25       Impact factor: 12.701

6.  Upregulation of GNL3 expression promotes colon cancer cell proliferation, migration, invasion and epithelial-mesenchymal transition via the Wnt/β-catenin signaling pathway.

Authors:  Xi Tang; Lang Zha; Hui Li; Gang Liao; Zhen Huang; Xudong Peng; Ziwei Wang
Journal:  Oncol Rep       Date:  2017-08-25       Impact factor: 3.906

7.  Prostate cancer susceptibility gene HIST1H1A is a modulator of androgen receptor signaling and epithelial to mesenchymal transition.

Authors:  Kendra A Williams; Minnkyong Lee; Jean M Winter; Derek E Gildea; Carla Calagua; Natasha L Curry; Jens Lichtenberg; Huihui Ye; Nigel P S Crawford
Journal:  Oncotarget       Date:  2018-06-19

8.  The Clock Is Ticking: Countdown to Metastases.

Authors:  Linda D Siracusa; Karen M Bussard
Journal:  PLoS Genet       Date:  2016-09-22       Impact factor: 5.917

Review 9.  Molecular determinants of prostate cancer metastasis.

Authors:  Kiera Rycaj; Dean G Tang
Journal:  Oncotarget       Date:  2017-09-19

10.  Modifier locus mapping of a transgenic F2 mouse population identifies CCDC115 as a novel aggressive prostate cancer modifier gene in humans.

Authors:  Jean M Winter; Natasha L Curry; Derek M Gildea; Kendra A Williams; Minnkyong Lee; Ying Hu; Nigel P S Crawford
Journal:  BMC Genomics       Date:  2018-06-11       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.